The computational biology market size was valued at USD 7.08 billion in 2025 and is projected to grow from USD 7.97 billion in 2026 to USD 21.01 billion by 2034, registering a CAGR of 12.88% during the forecast period (2026–2034). North America dominated the computational biology market with a market share of 44.20% in 2025.
Computational biology involves the use of mathematical models, algorithms, artificial intelligence, and computer-based tools to analyze biological data, understand complex systems, and accelerate scientific research. It supports drug discovery, genomics, proteomics, personalized medicine, disease modeling, and biotechnology by integrating large datasets with advanced computational techniques.
The computational biology market demand is driven by the growing investments in precision medicine, expanding genomic research, and rising adoption of AI across life sciences. Pharmaceutical companies and healthcare organizations are leveraging these platforms to improve research efficiency, accelerate innovation, and enhance clinical decision-making. Continuous technological advancements, increasing data availability, and collaborative research initiatives are also contributing to computational biology market growth.
Download a Free Sample To learn more about this report,
The computational biology market has indirect exposure to supply chain disruptions because it primarily depends on performance computing infrastructure, cloud servers, data storage systems, networking equipment, and specialized laboratory instruments that support biological data generation and analysis. Disruptions in the supply of semiconductors, servers, sequencing platforms, and data center hardware can delay computational infrastructure expansion, slow research activities, and limit the deployment of advanced computational biology solutions across pharmaceutical, biotechnology, and academic institutions worldwide. On a global scale, organizations are mitigating these challenges by diversifying technology suppliers, increasing cloud adoption, investing in regional data centers, and strengthening digital infrastructure resilience. The market is expected to experience a capacity-constrained recovery, with growth accelerating as hardware availability improves, cloud capacity expands, and infrastructure investments support increasing research and clinical demand.
Organizations are increasingly adopting AI-powered computational biology platforms that integrate genomics, transcriptomics, proteomics, metabolomics, and clinical datasets into unified analytical ecosystems. Instead of analyzing individual datasets separately, these platforms enable comprehensive biological insights, improving target identification, biomarker discovery, and precision medicine research. For example, Illumina integrates advanced bioinformatics and AI capabilities with sequencing technologies to support large-scale multi-omics analysis, enabling researchers to accelerate disease understanding and therapeutic development.
Another market trend is the increasing use of computational biology to develop digital twin models that simulate biological systems and predict patient-specific treatment responses. These virtual models enable researchers to evaluate disease progression, optimize drug candidates, and reduce dependence on traditional laboratory testing. For example, Dassault Systèmes, through its Living Heart and broader virtual twin initiatives, applies computational modeling to simulate biological processes, supporting drug development, personalized medicine, and advanced biomedical research.
The computational biology market forecasts sustained investment activity driven by increasing adoption of artificial intelligence in life sciences, expanding computational drug discovery, and growing demand for advanced bioinformatics platforms. Investors are prioritizing companies developing AI-enabled computational biology technologies, protein modeling platforms, and digital drug discovery solutions that accelerate biological research, improve target identification, and enhance precision medicine capabilities.
Key Investment and Funding Activities in Computational Biology Market, 2025
Isomorphic Labs
USD 600 million
In April 2025, the company completed its first external funding round led by Thrive Capital to scale its AI-powered computational biology and drug discovery platform, supporting therapeutic research and pharmaceutical partnerships.
Colossal Biosciences
USD 200 million (Series C)
In January 2025, the company raised Series C financing to expand AI-enabled computational genomics, species restoration programs, and biological engineering research, reaching a valuation of USD 10.2 billion.
Growing Expansion of Large-scale Genomics Programs and Rising Biopharmaceutical R&D Expenditure Drives Market
Governments and healthcare organizations are significantly expanding national genomics programs, generating unprecedented volumes of biological data that require advanced computational analysis. Large scale sequencing initiatives create demand for computational biology platforms capable of processing, storing, and interpreting genomic information for research and clinical applications. For example, the UK Biobank has collected genomic, imaging, and health data from 500,000 participants, while the All of Us Research Program has enrolled more than one million participants to build one of the world's largest precision medicine datasets. These population-scale programs are substantially increasing demand for computational biology software, high-performance analytics, and bioinformatics infrastructure worldwide.
The growing investment in pharmaceutical research and increasingly complex clinical development programs are accelerating the adoption of computational biology to improve target validation, biomarker discovery, toxicity prediction, and clinical data analysis. According to the Pharmaceutical Research and Manufacturers of America, biopharmaceutical companies invest billions of dollars annually in research and development, while clinical studies continue to generate increasingly complex genomic and molecular datasets requiring computational analysis. Additionally, regulatory agencies such as the US Food and Drug Administration continue to support the use of computational modeling and model-informed drug development approaches to improve development efficiency. The increasing scale and complexity of pharmaceutical R&D are driving sustained demand for computational biology solutions across drug discovery and clinical research.
High Computational Infrastructure Costs and Lack of Standardized Biological Data Restrain Market Expansion
Computational biology relies on high-performance computing infrastructure, cloud platforms, specialized software, and large-scale data storage, creating substantial operational costs for research organizations and healthcare institutions. Managing, securing, and processing massive genomic and biological datasets also require skilled personnel and advanced digital infrastructure. These financial and technical barriers limit adoption among smaller biotechnology firms, academic laboratories, and organizations with constrained research budgets.
Strict regulations governing genomic and patient health data, including privacy and cross-border data sharing requirements, complicate computational biology research and collaboration. Differences in data formats, quality, and annotation standards across research institutions further hinder interoperability and biological analyses. These regulatory and standardization challenges slow research workflows, increase compliance costs, and restrict seamless integration of diverse biological datasets across global research ecosystems.
Expansion of Precision Medicine and Rising Adoption of Computational Biology in Cell & Gene Therapy Offer Growth Opportunities to Market Players
The rapid expansion of precision medicine programs and national genomics initiatives is creating significant opportunities for computational biology solution providers. Countries are investing in large-scale genomic sequencing and population health research to improve disease prevention and personalized treatment strategies. These initiatives generate massive biological datasets requiring advanced computational analysis, creating sustained demand for bioinformatics platforms, AI analytics, and high-performance computing solutions across healthcare and life sciences.
The increasing development of synthetic biology, gene editing, and advanced cell and gene therapies is creating new opportunities for computational biology platforms. Researchers rely on computational models to optimize genetic engineering, predict biological interactions, and accelerate therapeutic design while reducing experimental timelines. For example, in 2025, Nucleate and Danaher Corporation launched the Global Gene Therapy Initiative to accelerate innovation in gene therapy through funding, mentorship, and technology access, further increasing demand for computational biology tools supporting complex biological modeling and therapeutic development.
Rapidly Expanding Biological Data and Shortage of Skilled Computational Biology & Bioinformatics Professionals Challenges Market Growth
A major challenge for the computational biology market is managing the exponential growth of genomic, proteomic, and multi-omics datasets generated through modern life sciences research. As sequencing technologies become faster and more affordable, organizations face increasing demands for scalable storage, high performance computing, and efficient data processing. The growing volume and complexity of biological data can create computational bottlenecks, increase infrastructure costs, and slow research workflows.
The limited availability of professionals with expertise in computational biology, bioinformatics, artificial intelligence, and data science remains a significant market challenge. Effective interpretation of complex biological datasets requires multidisciplinary knowledge spanning biology, statistics, and advanced computing. Many research institutions, biotechnology companies, and healthcare organizations face difficulties recruiting and retaining qualified talent, limiting the efficient adoption and utilization of advanced computational biology platforms.
Request Customizationto receive a tailored report.
Based on tool, the software platform & services segment accounted for a share of 37.85% in 2025, owing to seamless integration of multi-omics datasets, automated biological workflow management, and cloud-enabled collaborative research environments. These platforms also support reproducible computational pipelines, real-time data visualization, and scalable analytics essential for pharmaceutical development and translational research.
The database segment is expected to grow at a CAGR of around 13.07% during the forecast period due to increasing demand for curated biological repositories, standardized genomic reference datasets, and centralized molecular annotation resources. Expanding public and proprietary biological data collections are improving data accessibility, interoperability, and computational model accuracy.
In 2025, clinical trials accounted for a share of 25.93% in the computational biology market, by application, supported by biomarker-based patient stratification, molecular response analysis, and computational evaluation of treatment efficacy. These capabilities improve protocol optimization while enabling more precise patient selection across complex therapeutic studies.
The computational genomics segment is expected to grow at a CAGR of 13.56% during the forecast period, driven by increasing whole genome sequencing projects, rapid variant interpretation requirements, and large-scale comparative genomic analyses. Advanced computational algorithms enable faster identification of disease-associated genetic variations and functional genomic patterns.
By end use, the industrial segment is projected to grow at a CAGR of 13.75% during the forecast period, as biotechnology and pharmaceutical companies increasingly utilize computational biology for molecular design, protein engineering, and biologics optimization. Industrial users also leverage predictive modeling to improve manufacturing efficiency and therapeutic development outcomes.
The academic & research segment is expected to grow at a CAGR of 14.21% during the forecast period, driven by expanding collaborative life science research, increasing availability of open biological datasets, and wider adoption of computational methods in basic science investigations. Universities are integrating advanced computational tools into multidisciplinary biological research programs.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Expanding Genomics Research and Rising Biopharmaceutical Innovation
The North America computational biology market accounted for the largest regional share of 44.20% in 2025, driven by advanced genomics infrastructure, substantial biopharmaceutical research investments, and widespread adoption of computational technologies in drug discovery and precision medicine. The region benefits from strong collaboration between pharmaceutical companies, academic research institutions, and government agencies. According to the National Institutes of Health, the All of Us Research Program has enrolled more than one million participants, generating one of the world's largest health and genomic datasets that support computational biology research.
The US computational biology market was valued at USD 2.73 billion in 2025, driven by increasing investments in precision medicine, expanding pharmaceutical research, and rapid adoption of AI-enabled biological data analysis. Leading biotechnology companies, academic medical centers, and research organizations increasingly utilize computational biology for target discovery, biomarker identification, and clinical research. The country's robust biotechnology ecosystem, availability of high-performance computing infrastructure, and extensive government-funded genomics initiatives continue to accelerate market growth across research and healthcare applications.
The computational biology market in Canada was valued at USD 394.09 million in 2025, propelled by growing investments in genomics research, expanding bioinformatics capabilities, and increasing collaboration between universities, healthcare institutions, and biotechnology companies. National initiatives focused on precision medicine and population genomics are generating large scale biological datasets that require advanced computational analysis. Canada's strong research ecosystem, government funding for life sciences innovation, and increasing adoption of AI in biomedical research continue to support demand for computational biology solutions.
Asia Pacific: Fastest Growth Driven by Rapid Expansion of Tertiary Care Hospitals and Expansion of High-volume Surgical Facilities
The Asia Pacific computational biology market is expected to grow at a CAGR of 14.64% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding genomics research programs, increasing investments in biotechnology and pharmaceutical innovation, and rapid adoption of artificial intelligence in life sciences research. Governments across the region are strengthening precision medicine capabilities and bioinformatics infrastructure. According to the Japan Agency for Medical Research and Development, Japan continues to expand national genome research initiatives supporting precision medicine and computational life sciences.
The China computational biology market was valued at USD 382.83 million in 2025, accelerated by government investments in genomics, artificial intelligence, and biotechnology research. National precision medicine initiatives and expanding pharmaceutical R&D are increasing demand for computational biology platforms capable of analyzing complex biological datasets. The country's growing supercomputing infrastructure, increasing genomic sequencing capacity, and rapid expansion of biotechnology companies continue to strengthen adoption across research and drug discovery applications.
The India computational biology market was valued at USD 202.37 million in 2025, fueled by expanding bioinformatics research, increasing investments in biotechnology startups, and growing adoption of computational approaches in pharmaceutical development. Government initiatives such as the GenomeIndia Project are generating extensive genomic datasets that require advanced computational analysis. The country's expanding network of research institutes, life sciences organizations, and skilled computational professionals continues to support market growth.
The Japan computational biology market was valued at USD 233.49 million in 2025, supported by investments in precision medicine, aging related disease research, and advanced computational life sciences. The country's pharmaceutical industry increasingly utilizes computational biology for biomarker discovery, molecular simulation, and therapeutic development. Established research institutions, high performance computing capabilities, and continued government support for genomic medicine are accelerating the adoption of computational biology technologies across healthcare and biomedical research.
Unlock Regional Insightsto access country-level data, & regional trends.
The computational biology market competitive landscape is moderately fragmented, with competition driven by bioinformatics software providers, artificial intelligence companies, cloud computing vendors, and life sciences technology firms offering advanced biological data analysis solutions. Leading players compete through innovations in AI-powered analytics, multi-omics data integration, scalable cloud platforms, and strategic collaborations with pharmaceutical companies and research institutions. The computational biology market ecosystem is shaped by expanding genomics research, increasing precision medicine initiatives, rapid advances in computational technologies, evolving regulatory requirements for healthcare data, and growing demand for efficient, data-driven biological discovery and drug development solutions.
June 2026: Chai Discovery signed a license agreement with Pfizer, enabling Pfizer to deploy Chai’s AI platform and gain early access to the Chai-3 model.
May 2026: QIAGEN partnered with NVIDIA to integrate NVIDIA BioNeMo and accelerated computing with QIAGEN Digital Insights’ curated bioinformatics knowledge bases.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com